BICO Group AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0013647385
SEK
17.54
0.28 (1.62%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

100.56 k

Shareholding (Dec 2025)

FII

1.56%

Held by 2 FIIs

DII

98.44%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a fall in Net Sales of -12.39%, the company declared Very Negative results in Dec 25

  • OPERATING CASH FLOW(Y) Lowest at SEK 68.4 MM
  • PRE-TAX PROFIT(Q) At SEK -50.4 MM has Fallen at -119.38%
  • NET PROFIT(Q) At SEK -52.7 MM has Fallen at -120.02%
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,206 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.12

stock-summary
Return on Equity

-30.06%

stock-summary
Price to Book

0.69

Revenue and Profits:
Net Sales:
451 Million
(Quarterly Results - Dec 2025)
Net Profit:
-59 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.68%
0%
-7.68%
6 Months
-15.1%
0%
-15.1%
1 Year
-48.86%
0%
-48.86%
2 Years
-59.27%
0%
-59.27%
3 Years
-68.35%
0%
-68.35%
4 Years
-89.18%
0%
-89.18%
5 Years
-95.49%
0%
-95.49%

BICO Group AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
59.80%
EBIT Growth (5y)
-208.18%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.48
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.56%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.67
EV to EBIT
-8.32
EV to EBITDA
34.60
EV to Capital Employed
0.73
EV to Sales
1.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.72%
ROE (Latest)
-16.27%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (1.56%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -12.39% vs 29.72% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -123.63% vs 156.52% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "451.30",
          "val2": "515.10",
          "chgp": "-12.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "40.60",
          "val2": "104.10",
          "chgp": "-61.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "42.20",
          "val2": "26.90",
          "chgp": "56.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.60",
          "val2": "-5.30",
          "chgp": "-62.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.20",
          "val2": "250.50",
          "chgp": "-123.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34.30%",
          "val2": "-22.50%",
          "chgp": "-1.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -13.32% vs -14.09% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1,339.82% vs 86.05% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,497.20",
          "val2": "1,727.20",
          "chgp": "-13.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-17.80",
          "val2": "81.10",
          "chgp": "-121.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "68.20",
          "val2": "96.60",
          "chgp": "-29.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,066.00",
          "val2": "-134.20",
          "chgp": "-694.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,583.80",
          "val2": "-110.00",
          "chgp": "-1,339.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-157.00%",
          "val2": "-118.10%",
          "chgp": "-3.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
451.30
515.10
-12.39%
Operating Profit (PBDIT) excl Other Income
40.60
104.10
-61.00%
Interest
42.20
26.90
56.88%
Exceptional Items
-8.60
-5.30
-62.26%
Consolidate Net Profit
-59.20
250.50
-123.63%
Operating Profit Margin (Excl OI)
-34.30%
-22.50%
-1.18%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is -12.39% vs 29.72% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -123.63% vs 156.52% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,497.20
1,727.20
-13.32%
Operating Profit (PBDIT) excl Other Income
-17.80
81.10
-121.95%
Interest
68.20
96.60
-29.40%
Exceptional Items
-1,066.00
-134.20
-694.34%
Consolidate Net Profit
-1,583.80
-110.00
-1,339.82%
Operating Profit Margin (Excl OI)
-157.00%
-118.10%
-3.89%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -13.32% vs -14.09% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1,339.82% vs 86.05% in Dec 2024

stock-summaryCompany CV
About BICO Group AB stock-summary
stock-summary
BICO Group AB
Pharmaceuticals & Biotechnology
Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company operates as a provider of advanced bioprinting solutions for healthcare sector. The Company offers 3D bioprinting of human tissues and organs. The Company's technology facilitates the biofabrication of cell-laden anatomical structures with controlled cell density and homogenous distribution of viable cells. The cell-laden bioink structures are then cultured in vitro, under controlled conditions for a wide range of experiments. In addition, bioprinting with human cells can be combined with computer-aided design (CAD) and computer-aided manufacturing (CAM) using medical images from CT or MRI scans to create a blueprint (3D model) for bioprinting of patient-specific tissues and organs.
Company Coordinates stock-summary
Company Details
Arvid Wallgrens Backe 20 , GOETEBORG None : 413 46
stock-summary
Tel: 46 31 128700
stock-summary
Registrar Details